ABSENCE OF BCR-ABL KINASE DOMAIN MUTATIONS IN CHRONIC MYELOCYTIC LEUKEMIA (CML) QATARI PATIENTS ON IMATINIB MESYLATE (IM) TREATMENT

被引：0
|
作者：
Al-Dewik, I. [1 ]
Jewell, P. [2 ,3 ]
Elayoubi, R. [1 ]
Morsi, M. [4 ]
机构：
[1] Hmc Al Amal Oncol Ctr, Doha, Qatar
[2] Kingston Univ, London, England
[3] St Georges Univ, London, England
[4] Aquamed ME, Res & Educ Dept, Doha, Qatar
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1313
引用
收藏
页码：532 / 532
页数：1
相关论文
共 50 条
  • [1] Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Saffari, Zeinab
    Nadali, Fatemeh
    Ostadali, Mohammadreza
    Ghadimi, Habibeh
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    Rostami, Shahrbano
    HEMATOLOGY, 2013, 18 (06) : 327 - 332
  • [2] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Yuan Wei
    Mats Hardling
    Bob Olsson
    Rahil Hezaveh
    Anne Ricksten
    Dick Stockelberg
    Hans Wadenvik
    Annals of Hematology, 2006, 85 : 841 - 847
  • [3] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [4] Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
    Elias, Marjanu Hikmah
    Baba, Abdul Aziz
    Husin, Azlan
    Abdullah, Abu Dzarr
    Hassan, Rosline
    Sim, Goh Ai
    Wahid, S. Fadilah Abdul
    Ankathil, Ravindran
    HEMATOLOGY REPORTS, 2012, 4 (04) : 86 - 90
  • [5] BCR-ABL KINASE DOMAIN MUTATION FREQUENCY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT TO IMATINIB THERAPY
    Tikhonova, V.
    Misyurina, E.
    Kesaeva, L.
    Finashutina, Y.
    Krutov, A.
    Aksenova, E.
    Soldatova, I.
    Soldatkina, O.
    Ivanova, V.
    Novitskaya, N.
    Arshanskaya, E.
    Lazarev, I.
    Volkova, M.
    Pospelova, T.
    Konstantinova, T.
    Vysotskaya, L.
    Voloditcheva, E.
    Lapin, V.
    Davydkin, I.
    Turkina, A.
    Kolosheinova, T.
    Goryacheva, S.
    Chelysheva, E.
    Pristupa, A.
    Golubenko, R.
    Gavrilova, L.
    Volkova, S.
    Kuchma, G.
    Ovsyannikova, E.
    Zaklyakova, L.
    Kaplanov, K.
    Klitochenko, T.
    Misyurin, A.
    HAEMATOLOGICA, 2013, 98 : 548 - 548
  • [6] Increase of BCR-ABL/ABL Ratio That Corresponds to BCR-ABL Mutation Detection In Chronic Myeloid Leukemia (CML) Patients Treated by Imatinib (IM)
    Tsaur, Grigory
    Popov, Alexander
    Ivanova, Anna
    Yakovleva, Yulia
    Riger, Tatyana
    Plekhanova, Olga
    Ivanets, Yulia
    Shorikov, Egor
    Saveliev, Leonid
    Fechina, Larisa
    FASEB JOURNAL, 2011, 25
  • [7] Clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
    Nicolini, Franck
    HEMATOLOGIE, 2006, 12 (06): : 373 - 374
  • [8] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [9] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Hardling, M
    Wei, Y
    Palmqvist, L
    Swolin, B
    Stockelberg, D
    Gustavsson, B
    Ekeland-Sjöberg, K
    Wadenvik, H
    Ricksten, A
    MEDICAL ONCOLOGY, 2004, 21 (04) : 349 - 358
  • [10] Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
    Mats Hardling
    Yuan Wei
    Lars Palmqvist
    Birgitta Swolin
    Dick Stockelberg
    Bengt Gustavsson
    Kerstin Ekeland-Sjöberg
    Hans Wadenvik
    Anne Ricksten
    Medical Oncology, 2004, 21 : 349 - 358
12345